Formerly known as Activated Cell Therapy (ACT), Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development, commercialization, and manufacturing of novel therapeutics that may significantly improve cancer treatment options for patients. Following Chapter 11 Bankruptcy, the company was acquired in February 2015 by Valeant. In January 2017, that firm sold on Dendreon to the Sunpower Group. Dendreon applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response. Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development, commercialization, and manufacturing of novel therapeutics that may significantly improve cancer treatment options for patients. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response. Stil doingbsiness under the Dendreon name,the firm is headquartered in Seattle and has manufacturing facilities in New Jersey, Georgia, and California.
